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Purpose
Vaginal intraepithelial neoplasia (VAIN) is a rare condition, with 0.2-0.6 cases per 100,000 women, and the number of cases seem to be increasing [1, 2, 3] . Taking into account all grades of untreated VAIN, 78% regress, 13% persist, and 9% progress to invasion [4] . With this low incidence, there is no certain treatment, although brachytherapy is a valid option. However, considering the quite long-life expectancy, long-term side effects due to radiation must be taken into consideration.
Although some vaginal morbidity as a result of radiation to a specific part of the vagina is to be expected, the literature offers little data about dose-effect relationships in the vagina. The physical changes related to radiation have been well described, including adhesion of vaginal walls, narrowing and shortening of the vaginal barrel, and loss of elasticity. A concomitant decrease in vaginal secretions leads to dyspareunia, with a significant impact on quality of life [5, 6, 7, 8, 9] .
We describe a single-institution retrospective study of the application of high-dose-rate (HDR) brachytherapy (BT) as a radical treatment or treatment at the time of the first relapse of VAIN grade 3.
Material and methods
The records and treatment plans of 14 consecutive patients irradiated with HDR-BT between February 2010 and August 2016 for high-grade VAIN (grade 3) were analyzed. The following data were retrospectively collected for each case: patient demographics, clinical description of VAIN, previous treatments for VAIN, human papillomavirus (HPV) status, history of conization or hysterectomy, detailed description of BT, recurrence of VAIN or invasive vaginal carcinoma, and vital status.
HDR-BT was delivered using an iridium-192 ( 192 Ir) source from Elekta Microselectron (Elekta, Stockholm, Sweden). The intracavitary vaginal BT technique at our institution is based on the single-channel vaginal cylinder or multichannel applicators. All HDR-BT plans were generated, with a 3D treatment planning system (Oncentra Brachy Nucletron Elekta, Veenedaal, The Netherlands) to calculate the dose on computed tomography (CT) and magnetic resonance (MR) images. Doses were prescribed in high-risk clinical target volume (HR-CTV) defined as vaginal wall (5 mm depth), with cervical surface if existing.
Patients were followed-up for six weeks after treatment, then every three months for the first two years, and twice per year thereafter. Vaginal smears were taken every six months, and vaginoscopies and biopsies were obtained whenever required to confirm a recurrence.
Late complications of the vagina were graded during follow-up examination using the Common Terminology Criteria for Adverse Events v.4.0 (CTCAE 4.0) [10] . We specifically considered vaginal stenosis, telangiectasia, and vaginal bleeding defined as follows:
• Vaginal stenosis: mild vaginal shortening or narrowing: asymptomatic (G1); not interfering with physical examination (G2) or interfering with the use of tampons, sexual activity, or physical examination (G3); • Telangiectasia (TA): TA covering < 10% (G1) or > 10% (G2) of the vaginal mucosa; • Vaginal bleeding: minimal bleeding identified on clinical examination and with no indication to intervention (G1); moderate bleeding, in which medical intervention was indicated (G2); severe bleeding, for which transfusion was indicated (G3). Recurrent dysplasia or progression to invasive cancer was recorded from the last day of BT.
For the dose-report analysis, the International Commission on Radiation Units & Measurements (ICRU) of bladder and rectal points [11] were used as surrogate points of the anterior and posterior vaginal wall, respectively. Both points were defined according to the patient coordinate system on anterior-posterior lines, which were strictly perpendicular to the patient's longitudinal axis. However, we did not use a classical tandem and ovoid or tandem and ring for treatment, the rectal point was positioned from the top of the vaginal cylinder on a straight anterior-posterior line and on the intersection on the axis perpendicular to the body axis, 5 mm dorsal to the posterior vaginal wall.
The vaginal applicators used meant that the posterior-inferior order of the symphysis (PIBS) vaginal dose points were not useful to study the dose along the vaginal axis [12] . PIBS points were used to derive reference points as surrogates for the dose distribution at the mid-vagina, the transition from mid to lower, and at the lower vagina as follows:
• Point 1 (P1): from the PIBS (defined as 2 cm posterior to the posterior-inferior border of the pubic symphysis) on a straight anterior-posterior line perpendicular to the patient axis at the point where this line crosses the urethra; • Point 2 (P2): from P1, 2 cm up along the vaginal axis (at the level of PIBS+2); • Point 3 (P3): from P1, 2 cm down along the vaginal axis (at the level of PIBS-2) ( Figure 1 ). P1, P2, and P3 were at a median distance of 0.5 cm (range, 0.4-0.6) from the vaginal applicators.
For each fraction, we retrospectively collected the dose received by these points. Total doses were recalculated to the biologically equivalent doses and fractionation given with 2 Gy per fraction (EQD2) using the equation: EQD2 = nd (d + α/β)/(2 Gy + α/β), where n is the number of fractions and d the dose (Gy) per fraction (assuming α/β = 10 Gy for tumor control, and α/β = 3 Gy for late normal tissue damage). For vaginal tissue, we assumed α/β = 3 because of the non-invasive nature of VAIN.
Endpoints and statistical analysis
The aim of this paper was to report a single-institution study of the application of high-dose-rate BT and to evaluate clinical outcomes as well as to investigate the dose-effect relationship for vaginal stenosis.
For the present analyses, we used information recorded in the dataset about age, total and fractional doses in Gy and EQD2 units, doses received by each point (P1, P2, P3, rectal and bladder, as specified above), type and corresponding grade of toxicity, previous treatment for VAIN (yes/no), and previous hysterectomy (yes/no). First, we did a descriptive statistical analysis, and data were presented with a boxplot, radar plot (continuous variables), or bar chart (discrete variables). Second, we used distribution-free tests (appropriate for small data sets and lack of knowledge of the underlying distribution), with an explorative aim, since they suffer low power. We used the All statistical analyses were completed with the SAS (Version 9.4; SAS Institute, Inc., Cary, NC), adopting a significance level of α = 0.05.
Results

Patients
At diagnosis, all patients were asymptomatic, with HPV infection. Their ages ranged between 43 and 77 years (median, 60.5 years) and the median follow-up was 32.7 months (range, 10.5-89.83 months). Six patients had undergone hysterectomy for cervical cancer, three for cervical dysplasia, and one for benign disease. Two women had had previous treatment for VAIN grade 3, one with 5-fluorouracil (5-FU) 5% cream for vaginal self-application, and the other with laser ablation of the Lugol-identified vaginal lesion.
Treatments
All patients had plans for each fraction, and treatment was delivered twice a week for a mean of 15 days (range, 8-20 days). The total radiation dose range was 24-42 Gy, with a median of 35 Gy; the total recalculated EQD2 range was 43.2-75.6 Gy (median, 56 Gy). Fraction sizes are reported in Table 1 . Of the 14 registered patients, 13 had complete dosimetric data and were considered in the dosimetric analysis. Table 2 summarizes the doses received to P1, P2, P3, rectal, and bladder points.
After HDR-BT all patients used topical therapy with hyaluronic acid or/and vitamin E vaginal suppositories.
Complications of brachytherapy
Treatment was well tolerated, and no interruption was necessary. Acute toxicity was minimal, and most complaints were grade 1 urinary complications (5 patients). However, all patients had some late vaginal symptoms. During the follow-up, 5 patients developed vaginal stenosis G2 and 3 women had G3 (Figure 2 ). Since vaginal stenosis seemed to be the most frequent complaint, we focused our analysis by dichotomizing it on the basis of less than G2 or G2 and more.
Previous treatments for VAIN, previous hysterectomy, overall BT treatment time, total dose, and dose per fraction seemed not to be related to vaginal stenosis G ≥ 2. Total doses delivered to each point are presented and according to the grade of stenosis in Figure 3B . Per point dose and demographic analysis gave interesting ( Figure 3A ) results about the toxicity relationship with rectal point dose and age, respectively. Women with G ≥ 2 stenosis received a higher median dose ( Figures 3C and 4) and, in line with the published age cutoff, were > 60 years old ( Figure 5 ). No statistical significance was observed for these findings (Kruskal Wallis test: p = 0.391, Fisher's exact test: p = 0.286 for rectal dose and age analysis, respectively). However, the underpowered non-parametric test means it is hard to establish whether the real differences are only too small to be detected or actually do not exist.
Discussion
Treatment for VAIN is based on grade and focality (uni-or multifocal), and the treatment modalities available are medical, surgical, and radio-therapeutic. For selected healthy women, conservative management may be considered. Medical management, which can give cure rates of 45-100% is recommended for patients with persistent HPV infection and multifocal VAIN. It consists of trichloroacetic acid, 5-fluorouracil, and an immune response modifier (5% imiquimod, cidofovir). Therapeutic vaccine expressed HPV 16-18 oncoproteins E6 and E7, and poly-gamma-glutamic acid is still under investigation [13, 14, 15, 16, 17, 18, 19] .
Surgical treatments involve CO 2 laser ablation (successful in 70.8-79.2%), surgical excision (successful in 66-87%), cavitational ultrasonic surgical aspiration (CUSA), with a cure rate of 74% [20, 21, 22] . BT is acknowledged as an effective option, with high cure rates. In all reports, this treatment was well tolerated, with no limiting toxicities; the main late toxicity is vaginal, such as stenosis and ulcer (Table 3 ) [23, 24, 25, 26, 27, 28, 29] . After assessment by the multidisciplinary committee of gynecologic oncology, patients were selected for BT considering the multifocality of the disease. In our cohort, the HR-CTV is the whole length of the vagina because of the focality of VAIN. Since the vagina is also an organ at risk, we considered it worthwhile to assume α/β = 3 both for VAIN (a non-invasive disease) and for the whole vaginal tissue.
Vaginal BT may cause chronic vaginal alterations with direct damage to the vaginal mucosa, connective tissues, and microvasculature, resulting in secondary mucosal atrophy and increased collagen production that leads to shortening and tightening of the vagina. Pathological dilation of capillaries results in telangiectasia, tending to bleeding. In addition, adhesions and fibrosis cause loss of elasticity and some women may develop complete obliteration of vagina [30, 31, 32] .
Radiation-induced vaginal morbidity occurring within the first two years after the end of treatment is still a substantial problem, calling for further attention.
Since vaginal stenosis is the most frequent late effect and tends to persist, we focused our toxicity analysis on this issue. The damage to the epithelium was exacerbated by menopausal status, resulting in a further decrease in lubrication and thinning of vaginal tissues. Patients with stenosis more than or equal to 2 accounted for 86% and 29%, respectively, among the over-60s and those aged 60 or less.
A points-based reporting method is generally used for the dose evaluation of bladder and rectum, but no clear recommendations for dose-volume parameters of the vagina have been developed so far. In the Embrace study (image-guided intensity-modulated external beam radiochemotherapy and MRI-based adaptive brachytherapy in locally advanced cervical cancer), the ICRU rectal point is suggested as a surrogate point to predict vaginal morbidity. Kirchheiner et al. showed an increase in the risk of vaginal stenosis for increasing the EQD 2 dose to the reference recto-vaginal point, and a planning aim of 85 Gy EQD 2 (sum of external beam radiotherapy and BT) was proposed in order to reduce morbidity [33] .
In our study, women who received a higher median dose to the rectal point developed major vaginal stenosis, even though we did not find any statistically significant evidence. Since non-parametric tests can suffer low power mainly due to small sample size, there may be a true effect or just a smaller difference that the underpowered non-parametric test cannot detect. For this reason, our results need to be reassessed in future studies.
Total dose and dose per fraction did not seem related to G ≥ 2 vaginal stenosis. It is worth noting that one woman who received a total dose of 24 Gy in four fractions presented G3 toxicity after a follow-up of 37.53 months.
Major limitations of this study are the small sample and the retrospective analysis. However, the findings might prove useful as a starting point, since the rarity of this malignancy and limited BT approach for VAIN would require substantial resources for prospective studies.
Conclusions
This study found that HDR-BT was an effective, feasible, and well tolerated treatment for VAIN. In spite of high cure rates, we must still clarify issues regarding vaginal toxicity, the woman's age, and the total dose delivered to the rectal point in order to reduce complications.
Applicable dose limits to the vagina are needed to apply them when planning therapy to improve patients' quality of life. Therefore, this field merits further investigation to reach robust and significant results.
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